CPI 613

Drug Profile

CPI 613

Alternative Names: Bylantra; CPI-613

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cornerstone Pharmaceuticals; Stony Brook University
  • Developer Cornerstone Pharmaceuticals; National Cancer Institute (USA); Rafael Pharmaceuticals; Wake Forest University School of Medicine
  • Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Thiophenes
  • Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myelodysplastic syndromes; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Phase I/II Cancer
  • Phase I Acute myeloid leukaemia; Biliary cancer; Colorectal cancer; Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Sep 2017 Cornerstone Pharmaceuticals plans a pivotal phase II/III trial for Pancreatic cancer in 2018
  • 05 Jun 2017 Cornerstone Pharmaceuticals is now called Rafael Pharmaceuticals
  • 09 May 2017 Updated efficacy data from a phase I trial in Pancreatic caner (Combination therapy) released by Cornerstone Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top